90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr - Wikidata - wikimedia - TriplyDB

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr

http://www.wikidata.org/entity/Q26776480

about

Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

P2860

Q26744088-6D38CAFF-41D9-4913-8CE5-C70A3302A54D Q50200754-B2BA9E7D-2DA1-4B12-AB09-289CD1C55C40

P2860

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr

http://www.wikidata.org/entity/Q26776480

description

2016 nî lūn-bûn

@nan

2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr

@ast

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr

@en

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr

@nl

type

label

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr

@ast

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr

@en

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr

@nl

prefLabel

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr

@ast

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr

@en

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr

@nl

P1433

Q26776480-3DB0185B-F7D5-4085-AFC9-70E553EBB571

P1476

Q26776480-AA2A1C6E-1933-4BBB-A989-750DE21D6069

P2093

Q26776480-43CDBB09-4922-4B34-9D67-126EA80A13B8

Q26776480-72280C5A-B4AA-40AE-975D-4F60E22B4A0D

P275

Q26776480-B0DCC93B-3723-458E-8A6F-BDE90B8EC7D9

P2860

Q26776480-0E73A0DE-BEB6-4335-984A-9702CBF2BF1A

Q26776480-1F566161-63E8-4313-814C-64442A555117

Q26776480-22B9677D-15BE-414E-8A2B-8093998A152C

Q26776480-2480FE16-D683-41EA-90DD-AA9C5EDB6BE6

Q26776480-42DF91A9-433A-457D-AADD-15DDAA40E3DB

Q26776480-49003AC7-CCBF-4992-9052-632E7B3E4CA3

Q26776480-5686ACB3-07D9-46D4-B4D1-A736082C49C5

Q26776480-5B6757FA-DEE1-426F-833F-E1A9EADCD822

Q26776480-5DE70CD8-72A2-4FA1-8F94-ACB93AEBE0CA

Q26776480-5E20AC46-09DF-418D-9AF2-032296DD10BE

P304

Q26776480-56491658-D2B8-4530-9C3F-C3BEF64E5CE5

P31

Q26776480-369470E0-01B3-4023-A8F3-920D9318FD1E

P3181

Q26776480-3821DD5E-CA44-404F-8C63-7F30971DE0CE

P356

Q26776480-BD53CBF3-D25F-4B7C-8CC2-9B9B8CE61FA1

P407

Q26776480-BFA9564B-C88F-4D87-9D52-786C2BCA8BAE

P433

Q26776480-0F391D37-2135-4F56-BA55-1BBA0CA325C7

P478

Q26776480-B98A6EF3-41B1-4C43-824A-360F517B801A

P50

Q26776480-16E2F250-2D63-4FF9-A298-12D91DC44524

Q26776480-CFB40EF7-74A6-4B82-B84A-B0CF4F935DB7

P5008

Q26776480-F63B2464-33C7-4D62-AD35-1D614BC1F333

P577

Q26776480-4D0E5D53-C1C1-4F3E-9ACA-F221D8AA14F6

P5875

Q26776480-CD2F939F-6EA9-4789-BEA6-2D70BC72590A

P698

Q26776480-7E8C821B-6741-4C48-A1BF-98276E4F7A21

P921

Q26776480-3052E95C-7CC7-4405-A1C3-94E5B42BE232

Q26776480-3FF0095A-B878-464F-A76D-8F160A4B0AE3

Q26776480-8989D7A3-9D35-423D-B163-B3B7DB38CFAC

Q26776480-B153B802-E371-4991-B2FB-270608966026

Q26776480-F61F01F7-1AC2-40A0-87AA-5BD9FD117AE2

P932

Q26776480-696E905A-A18F-4380-8F36-FB7E3CD87089

P3181

P356

ONCOTARGET.6531

P1433

P1476

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr

@en

P2093

Michael Mian

http://www.w3.org/2001/XMLSchema#string

Michele Navarra

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.

Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.

Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.

Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.

A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

P304

7597-7609

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1391823

http://www.w3.org/2001/XMLSchema#string

P356

10.18632/ONCOTARGET.6531

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Salvatore Cuzzocrea

P5008

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286983293

http://www.w3.org/2001/XMLSchema#string

P698

26657116

http://www.w3.org/2001/XMLSchema#string

P921

inorganic compound

diffuse large B-cell lymphoma

monoclonal antibody

P932

4884941

http://www.w3.org/2001/XMLSchema#string